Vibostolimab Coformulated With Pembrolizumab Showed Promising Activity Among Patients With dMMR Endometrial Cancer
According to the phase 2 KEYVIBE-005 study, vibostolimab coformulated with pembrolizumab showed durable antitumor activity with a manageable safety profile among patients with previously treated advanced mismatch repair deficient (dMMR) endometrial cancer.
These data will be presented by Carlos Rojas, MD, Bradford Hill Clinical Research Center, Santiago, Chile, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
Cohort B1 of this phase 2 study enrolled 40 patients with advanced dMMR endometrial cancer who had progressive disease after platinum-based chemotherapy and had not received prior PD-1/PD-L1 therapy. All patients received 200 mg vibostolimab coformulated with 200 mg pembrolizumab 3 times a week for ≤35 cycles. The primary end point of this study was objective response rate (ORR) and second end points included duration of response (DOR) and progression-free survival (PFS), overall survival (OS), and safety.
The ORR was 65%, including 5 patients (13%) with a complete response and 21 patients (53%) with a partial response. The median DOR 13.7 months. The median PFS was 15.0 months and the 12-month PFS rate was 58%. The median OS was not reached, and the 12-month OS rate was 82%.
As the study authors concluded, this formulation of vibostolimab and pembrolizumab “demonstrated durable antitumor activity and a manageable safety profile” among patients with previously treated advanced dMMR endometrial cancer.
Source:
Rojas C, Eskens F, Ghiringhelli F, et al. Vibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repair–deficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study. Presented at the ASCO Annual Meeting. May 31 – June 4, 2024; Chicago, IL. Abstract #5502
